|Year to 31st March|
|Sales excluding precious metals||1,886||1,797||+5|
|Profit before tax||228.5||249.4||-8|
|Total earnings per share||77.6p||82.6p||-6|
|Profit before tax||254.1||267.9||-5|
|Earnings per share||86.4p||89.6p||-4|
|*||Before amortisation of acquired intangibles, major impairment and restructuring charges and profit or loss on disposal of businesses.|
Revenue for the year ended 31st March 2010 was in line with last year at £7.8 billion, although performance was biased towards the second half of the year due to the increase in activity and precious metal prices; first half revenue was £3.6 billion and second half revenue was £4.2 billion. Despite the economic background, the group’s sales excluding precious metals held up well and were 5% higher than last year at £1,886 million. Translated at constant exchange rates, revenue for the year fell by 3% and sales excluding precious metals grew by 1%.
Our new heavy duty diesel catalyst manufacturing facility in western Pennsylvania, USA.
Underlying operating profit (before amortisation of acquired intangibles, major impairment and restructuring charges) was 9% lower than last year at £271.8 million. The group benefited from the weakness of sterling and at constant exchange rates underlying operating profit would have been 13% lower than last year.
This year we have taken an impairment charge in respect of redundant assets at our Pharmaceutical Materials and Services contract research business in Massachusetts, USA. This resulted in a charge of £11.3 million which has been excluded from underlying earnings per share.
The performance of the individual businesses is explained in more detail in the Operations Review section.